[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620720":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":32,"responsibleParty":227,"collaborators":10,"id":229,"slug":230,"hasResults":231,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":235,"eligibilityCriteria":236,"healthyVolunteers":231,"sex":237,"minAge":238,"maxAge":10,"enrollmentInfo":239,"targetDuration":10,"studyType":242,"phases":10,"briefSummary":243,"conditions":244,"keywords":246,"overallStatus":52,"whyStopped":10,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":257},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Cohort 1",null,"Participants with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) receiving mavacamten",[13],"Drug: Mavacamten",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DRUG","Mavacamten","According to the product label",[9],[21],{"name":22,"affiliation":5,"role":23},"Bristol Myers Squibb","STUDY_DIRECTOR",[25,30],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"BMS Clinical Trials Contact Center www.BMSClinicalTrials.com","CONTACT","855-907-3286","Clinical.Trials@bms.com",{"name":31,"role":27,"phone":10,"phoneExt":10,"email":10},"First line of the email MUST contain NCT # and Site #.",[33,50,60,70,83,97,110,123,137,151,164,175,189,202,214],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Local Institution - 0008","NOT_YET_RECRUITING","Beijing","Beijing Municipality","100029","China","CN",{"type":42,"coordinates":43},"Point",[44,45],116.39723,39.9075,{"lat":45,"lon":44},[48],{"name":49,"role":27,"phone":10,"phoneExt":10,"email":10},"Site 0008",{"facility":51,"status":52,"city":36,"state":37,"zip":53,"country":39,"countryCode":40,"cosmosGeoPoint":54,"geoPoint":56,"contacts":57},"Peking Union Medical College Hospital","RECRUITING","100032",{"type":42,"coordinates":55},[44,45],{"lat":45,"lon":44},[58],{"name":59,"role":27,"phone":10,"phoneExt":10,"email":10},"Zhuang Tian, Site 0001",{"facility":61,"status":52,"city":36,"state":37,"zip":62,"country":39,"countryCode":40,"cosmosGeoPoint":63,"geoPoint":65,"contacts":66},"Peking University First Affiliated Hospital","100034",{"type":42,"coordinates":64},[44,45],{"lat":45,"lon":44},[67],{"name":68,"role":27,"phone":69,"phoneExt":10,"email":10},"Ma Wei, Site 0002","86-13681050902",{"facility":71,"status":35,"city":72,"state":73,"zip":74,"country":39,"countryCode":40,"cosmosGeoPoint":75,"geoPoint":79,"contacts":80},"Local Institution - 0009","Guangzhou","Guangdong","510080",{"type":42,"coordinates":76},[77,78],113.25,23.11667,{"lat":78,"lon":77},[81],{"name":82,"role":27,"phone":10,"phoneExt":10,"email":10},"Site 0009",{"facility":84,"status":52,"city":85,"state":86,"zip":87,"country":39,"countryCode":40,"cosmosGeoPoint":88,"geoPoint":92,"contacts":93},"The Second Afilliated Hospital of Hebei Medical University","Jiazhuang","Hebei","050000",{"type":42,"coordinates":89},[90,91],114.03858,38.09919,{"lat":91,"lon":90},[94],{"name":95,"role":27,"phone":96,"phoneExt":10,"email":10},"Xinshun Gu, Site 0014","+86 13930139688",{"facility":98,"status":35,"city":99,"state":100,"zip":101,"country":39,"countryCode":40,"cosmosGeoPoint":102,"geoPoint":106,"contacts":107},"Local Institution - 0003","Harbin","Heilongjiang","150086",{"type":42,"coordinates":103},[104,105],126.65,45.75,{"lat":105,"lon":104},[108],{"name":109,"role":27,"phone":10,"phoneExt":10,"email":10},"Site 0003",{"facility":111,"status":35,"city":112,"state":113,"zip":114,"country":39,"countryCode":40,"cosmosGeoPoint":115,"geoPoint":119,"contacts":120},"Local Institution - 0007","Zhengzhou","Henan","450052",{"type":42,"coordinates":116},[117,118],113.64861,34.75778,{"lat":118,"lon":117},[121],{"name":122,"role":27,"phone":10,"phoneExt":10,"email":10},"Site 0007",{"facility":124,"status":52,"city":125,"state":126,"zip":127,"country":39,"countryCode":40,"cosmosGeoPoint":128,"geoPoint":132,"contacts":133},"Suzhou Municipal Hospital","Suzhou","Jiangsu","215002",{"type":42,"coordinates":129},[130,131],120.59538,31.30408,{"lat":131,"lon":130},[134],{"name":135,"role":27,"phone":136,"phoneExt":10,"email":10},"Yan Chen, Site 0015","+86 18015571559",{"facility":138,"status":52,"city":139,"state":140,"zip":141,"country":39,"countryCode":40,"cosmosGeoPoint":142,"geoPoint":146,"contacts":147},"The Second Hospital of Jilin University","Changchun","Jilin","130041",{"type":42,"coordinates":143},[144,145],125.32278,43.88,{"lat":145,"lon":144},[148],{"name":149,"role":27,"phone":150,"phoneExt":10,"email":10},"Bin Liu, Site 0004","+86043188796598",{"facility":152,"status":35,"city":153,"state":154,"zip":155,"country":39,"countryCode":40,"cosmosGeoPoint":156,"geoPoint":160,"contacts":161},"Local Institution - 0005","Dalian","Liaoning","116011",{"type":42,"coordinates":157},[158,159],121.60222,38.91222,{"lat":159,"lon":158},[162],{"name":163,"role":27,"phone":10,"phoneExt":10,"email":10},"Site 0005",{"facility":165,"status":166,"city":167,"state":168,"zip":169,"country":39,"countryCode":40,"cosmosGeoPoint":170,"geoPoint":174,"contacts":10},"Local Institution - 0013","WITHDRAWN","Xi'an","Shan3xi","710061",{"type":42,"coordinates":171},[172,173],108.92861,34.25833,{"lat":173,"lon":172},{"facility":176,"status":52,"city":177,"state":178,"zip":179,"country":39,"countryCode":40,"cosmosGeoPoint":180,"geoPoint":184,"contacts":185},"West China Hospital of Sichuan University","Chengdu","Sichuan","610041",{"type":42,"coordinates":181},[182,183],104.06667,30.66667,{"lat":183,"lon":182},[186],{"name":187,"role":27,"phone":188,"phoneExt":10,"email":10},"Yucheng Chen, Site 0012","+86 18980602149",{"facility":190,"status":52,"city":191,"state":192,"zip":193,"country":39,"countryCode":40,"cosmosGeoPoint":194,"geoPoint":198,"contacts":199},"The Second Affiliated Hospital of Zhejiang University School of Medicine","Hangzhou","Zhejiang","310009",{"type":42,"coordinates":195},[196,197],120.16142,30.29365,{"lat":197,"lon":196},[200],{"name":201,"role":27,"phone":10,"phoneExt":10,"email":10},"Xiaojie Xie, Site 0006",{"facility":203,"status":35,"city":204,"state":10,"zip":205,"country":39,"countryCode":40,"cosmosGeoPoint":206,"geoPoint":210,"contacts":211},"Local Institution - 0010","Jinan","250012",{"type":42,"coordinates":207},[208,209],116.99722,36.66833,{"lat":209,"lon":208},[212],{"name":213,"role":27,"phone":10,"phoneExt":10,"email":10},"Site 0010",{"facility":215,"status":52,"city":216,"state":10,"zip":217,"country":39,"countryCode":40,"cosmosGeoPoint":218,"geoPoint":222,"contacts":223},"Zhongshan Hospital Fudan University","Shanghai","200032",{"type":42,"coordinates":219},[220,221],121.45806,31.22222,{"lat":221,"lon":220},[224],{"name":225,"role":27,"phone":226,"phoneExt":10,"email":10},"Shuning Zhang, Site 0011","+86 15921766132",{"type":228,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100620720","a-study-to-assess-the-real-world-effectiveness-of-mavacamten-in-adult-patients-with-obstructive-hypertrophic-cardiomyopathy-in-china-100620720",false,"NCT07361289","A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China","A Single-Arm Observational Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China","SOAR-HCM","Inclusion Criteria:\n\n* Participants aged ≥ 18 years (participants enrolled retrospectively: at the time of initial mavacamten prescription), irrespective of gender.\n* Participants who have initiated mavacamten (for whom enrolled retrospectively) or are scheduled to initiate mavacamten (for whom enrolled prospectively) based on clinical therapeutic needs.\n* Diagnosed with obstructive hypertrophic cardiomyopathy (HCM) consistent with current American College of Cardiology Foundation\u002FAmerican Heart Association, European Society of Cardiology, and Chinese guidelines for diagnosis and treatment of patients with hypertrophic cardiomyopathy, i.e., satisfy criteria below:\n\n  * Has a documented diagnosis of HCM prior to enrollment, and\n  * Peak left ventricular outflow tract (LVOT) gradient ≥ 30 mmHg at rest or with provocation in the most recent medical record within 3 months prior to enrollment as assessed by echocardiography.\n* Has documented left ventricular ejection fraction (LVEF) ≥ 55%, as measured by resting transthoracic echocardiography (TTE) in the most recent medical record within 3 months prior to enrollment.\n* New York Heart Association (NYHA) class II or III symptoms in the most recent medical record within 3 months prior to enrollment.\n* For participants enrolled retrospectively, essential baseline information\\* and critical data\\*\\* must be traceable and available. At least one key follow-up time points\\*\\*\\* is required for inclusion.\n\nNote：\n\n\\* Essential baseline information, including age, gender, resting or provoked LVOT peak gradient, LVEF, indices of cardiac structure (e.g., maximum LV wall thickness, atrial and ventricular chamber size and volumes), as well as systolic and diastolic function, NYHA functional class.\n\n* Critical data, including resting or provoked LVOT gradient, LVEF, cardiac structure, systolic and diastolic function, dose of mavacamten.\n\n  * Key follow-up time points: including weeks 4, 8, 12, 24, 36, 48, 72 and 96.\n\n    * Voluntary sign informed consent form. Note: For participants enrolled retrospectively, the most recent medical record within 3 months as mentioned in the above requirements refer to the most recent medical record within 3 months prior to the initial mavacamten prescription.\n\nExclusion Criteria:\n\n* Known HCM phenocopy disease (e.g., Fabry disease, amyloidosis).\n* Participants who are expected to undergo major cardiac surgery during the study.\n* Prior treatment of obstructive HCM with invasive septal reduction (surgical myectomy or percutaneous alcohol septal ablation \\[ASA\\] or septal radiofrequency ablation) within 6 months prior to enrollment (participants enrolled retrospectively: within 6 months prior to initial mavacamten prescription); participants with an unsuccessful myectomy or percutaneous ASA or septal radiofrequency ablation performed \\>6 months prior to enrollment (participants enrolled retrospectively: within 6 months prior to initial mavacamten prescription) may be enrolled.\n* Currently treated with disopyramide or ranolazine (within 14 days prior to enrollment \\[participants enrolled retrospectively: within 14 days prior to initial mavacamten prescription\\]) or participants who are expected to be taking disopyramide, ranolazine, verapamil in combination with β-receptor blockers, or diltiazem in combination with β-receptor blockers during the study.\n* Presence of other diseases that may affect completion of 96 weeks follow-up as assessed by the investigator.\n* Participants who are using or are expected to be using moderate to strong CYP2C19 inhibitors\u002Finducers, or strong CYP3A4 inhibitors, moderate to strong CYP3A4 inducers during the study.\n* Participants who are participating in other interventional clinical studies.","ALL","18 Years",{"count":240,"type":241},500,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to assess the effectiveness of mavacamten treatment in Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM) in real-world clinical practice",[245],"Hypertrophic Cardiomyopathy",[247],"Obstructive hypertrophic cardiomyopathy (oHCM)","2026-06-17",{"date":250,"type":251},"2026-06-18","ACTUAL",{"date":253,"type":251},"2026-01-15",{"date":255,"type":241},"2028-08-28",{"name":5,"class":6},15]